Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial

FHS
April 9, 2024
2:03 am

A study in The New England Journal of Medicine evaluates the combination of nirmatrelvir and ritonavir against COVID-19, finding it does not significantly reduce symptom duration in vaccinated or unvaccinated adult outpatients.

Annual General Meeting of Kuros Biosciences approves all resolutions – Biotech Investments

Kuros Biosciences AG / Key word(s): AGMEGM Annual General Meeting of Kuros Biosciences approves all resolutions 17.04.2024 / 14:05 CET/CEST Schlieren (Zurich), Switzerland, April 17,

April 18, 2024

Trial Supports GLP-1 After Underwhelming Metabolic Surgery

Adding a GLP-1 receptor agonist to lifestyle intervention helped to bolster weight loss in patients with poor outcomes following primary metabolic surgery, the BARI-OPTIMISE randomized

July 28, 2023

H1 2024 RESULTS – Major advances in all three programs – Several strategic agreements signed with the world medtech leader in cardiology – Extension of financial runway – Biotech Investments

EQS-News: Affluent Medical SA / Key word(s): Half Year Results Affluent Medical SA: H1 2024 RESULTS – Major advances in all three programs – Several

September 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.